title: Transplacental transfer and metabolism of buprenorphine.
abstract: Information on the direct and indirect effects of buprenorphine (BUP) on the fetus is essential for determining its potential for treatment of the pregnant opiate addict. The goal of this investigation is to determine the transplacental transfer of BUP to the fetal circulation, its metabolism, and effects on the tissue. The technique of dual perfusion of placental lobule is used. The range of BUP concentrations investigated included its peak plasma levels (10 ng/ml) in patients under treatment. A biphasic decline in concentration of the drug in the maternal circulation was observed, initially rapid then slow. During the initial (60 min), the tissue sequestered most of BUP resulting in a low (<10%) transplacental transfer of the drug to the fetal circulation. The concentration ratios of the drug in tissue/maternal and tissue/fetal were 13 +/- 6.5 and 27.4 +/- 0.4. The drug sequestered did not have any adverse effects on placental tissue viability and functional parameters. Less than 5% of the perfused BUP was metabolized to norbuprenorphine during the 4 h of perfusion and the metabolite was distributed between the tissue, maternal, and fetal circulations. Taken together, these data suggest that the therapeutic levels of BUP in the maternal circulation may have no indirect effects (via the placenta) on the fetus. The observed low transplacental transfer of BUP to the fetal circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the drug during pregnancy.
authors.affiliation: Division of Pharmacology, School of Medicine, University of Missouri, Kansas City, Missouri 64108-2792, USA.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Nanovskaya
authors.forename: Sujal
authors.initials: S
authors.lastname: Deshmukh
authors.forename: Monica
authors.initials: M
authors.lastname: Brooks
authors.forename: Mahmoud S
authors.initials: MS
authors.lastname: Ahmed
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics; D000983:Antipyrine / Q000493:pharmacokinetics; D001711:Biotransformation; D002047:Buprenorphine / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D009292:Narcotic Antagonists / Q000493:pharmacokinetics*; D010920:Placenta / Q000378:metabolism* / Q000502:physiology; D011247:Pregnancy; D011957:Receptors, Opioid / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D002047:Buprenorphine; D000983:Antipyrine